| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62f941494409aea84f621977c5f0ab81 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-582
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbaf1af593dd3af369c74d3dc4dd455e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0ec333f1e1827b52ce20f8a88e29cf7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa65fcf02d0b70c6e1b3a2121efe65ae |
| publicationDate |
2020-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3112799-A1 |
| titleOfInvention |
Compositions and methods for immunotherapy profiling |
| abstract |
: Compositions and methods for pharmacodynam-ic monitoring of immunotherapy are provided herein. The com-positions include an immunotherapeutic agent linked to protease substrates. Upon administration, the compositions target to sites of disease where proteases are upregulated during responsive im-munotherapy and subsequently cleave the attached substrates. Cleavage fragments are detected in a sample from the body and detection of the fragments is indicative of an effect of the im-munotherapeutic agent. WO 2020/055952 Al 11111 1111111111111111 ON IN 11111 11 II II III 11111 11111 Ell 11111 III I II 11E11E1111 111111 Declarations under Rule 4.17: ¨ as lo applicant's enlillement to apply for and be granted a patent (Rule 4.1700 ¨ as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: ¨ with international search report (Art. 21(3)) Date Recue/Date Received 2021-03-11 |
| priorityDate |
2018-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |